KISQALI FEMARA CO-PACK

Novartis Pharmaceuticals Corporation🇺🇸 United States

FDA Page

Effective Date: Jul 1, 2026
Approval ID: aa5e4446-19cd-4235-a382-5b48bf6c3b2f
Products: 3 registered
Version: 26

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use KISQALI FEMARA CO-PACK safely and effectively. See full prescribing information for KISQALI FEMARA CO-PACK. KISQALI FEMARA CO-PACK (ribociclib tablets; letrozole tablets), co-packaged for oral useInitial U.S. Approval: 2017

Quick Stats

Total Products3

Labelers2

Label Sections20

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.